Announcements
- Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
- Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
- Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
- Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
More ▼
Key statistics
As of last trade Xenon Pharmaceuticals Inc (XP0:FRA) traded at 40.00, -14.16% below its 52-week high of 46.60, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.00 |
---|---|
High | 40.00 |
Low | 40.00 |
Bid | 40.00 |
Offer | 40.20 |
Previous close | 39.40 |
Average volume | 150.22 |
---|---|
Shares outstanding | 75.47m |
Free float | 74.29m |
P/E (TTM) | -- |
Market cap | 3.30bn USD |
EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:02 BST.
More ▼